Gil Kliman is a Managing Director of InterWest Partners, a leading diversified venture capital firm. At InterWest, he focuses on life sciences investing, with a special interest in medical devices and ophthalmology.
He was one of the early lead investors in IntraLase (ILSE), an ophthalmic laser company that completed a highly successful IPO in 2004 and was acquired by AMO in 2007 for $808 million, as well as LenSx, the first femtosecond laser cataract surgery company, which was acquired by Alcon in 2010 for a total transaction value of $744 million.
Prior to InterWest Partners, Dr. Kliman was a healthcare investor at TA Associates and at Norwest Venture Capital.
Dr. Kliman did a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation Fellow, where he conducted and published the first studies of photodynamic therapy for macular degeneration. He also serves as a National Trustee for the Foundation Fighting Blindness.
Dr. Kilman completed his ophthalmology residency at Wills Eye Hospital, and holds an MD from the University of Pennsylvania, an MBA from Stanford, and a BA from Harvard.